skip to Main Content

bm|t sells holdings in CLONDIAG chip technologies

  • 2006

US Diag­nos­tics Com­pany buys into Jena

bm|t beteili­gungs­man­age­ment thuerin­gen GmbH has sold its hold­ings in CLONDIAG chip tech­nolo­gies GmbH in Jena, enabling the Amer­i­can diag­nos­tics com­pany Inver­ness Med­ical Inno­va­tions Inc. to enter this area of busi­ness. Inver­ness is ini­tially tak­ing a total of 67% of the hold­ings, pay­ing 3.1 mil­lion dol­lars for it as well as a shares pack­age. On 31 August 2006, 4.9 mil­lion dol­lars will be paid for the remain­der and for fur­ther shares. At the same time, the pur­chaser has under­taken oblig­a­tions to a total of over 10 mil­lion dol­lars. “The sale of our hold­ings opens up var­i­ous strate­gic options for the com­pany”, stated bm|t man­ag­ing direc­tor Dr Guido Bohnenkamp in Erfurt.

CLONDIAG was founded in 1998 and suc­cess­fully devel­ops and pro­duces its own prod­ucts for research and clin­i­cal diag­nos­tics. Minia­turised, reli­able diag­no­sis sys­tems enable com­plex mol­e­c­u­lar bio­log­i­cal analy­ses to be car­ried out very quickly, sim­ply and eco­nom­i­cally. Thou­sands of tests in par­al­lel are pos­si­ble. The involve­ment of Inver­ness pro­vides syn­ergy effects and so opens up oppor­tu­ni­ties for more rapid and wider pen­e­tra­tion of the mar­ket, par­tic­u­larly in the point-of-care area.

bm|t has been sup­port­ing CLONDIAG finan­cially and in terms of busi­ness man­age­ment since the end of 1999.

Inver­ness Med­ical Inno­va­tions has its head­quar­ters in Waltham, Mass­a­chu­setts and is a lead­ing com­pany world­wide in the pro­duc­tion and sale of in vitro diag­no­sis prod­ucts – for exam­ple, for preg­nancy and fer­til­ity tests and other pro­fes­sional rapid tests for clin­i­cal diag­no­sis. In 2005, Inver­ness had an annual turnover of over 400 mil­lion dol­lars and employs around 1,700 staff. Its prod­ucts are sold world­wide, par­tic­u­lar tar­gets being USA, Ger­many, France, Spain and Scandinavia.

Back To Top
×Close search
Search